Gene test could predict who benefits from common diabetes pill
NCT ID NCT04323189
Summary
This small study aims to understand if people with a specific genetic variation that lowers a certain enzyme (DPP4) respond differently to the diabetes drug sitagliptin. Twenty participants, half with the gene variant and half without, will take the drug and a placebo for short periods. Researchers will measure their blood sugar, hormone levels, and heart function after meals to see if the genetic difference changes how the drug works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.